ERBB2 and breast carcinoma: The Southwest Oncology Group (SWOG) S1501 trial (NCT03418961) is a randomized phase III trial investigating the efficacy of the beta-blocker carvedilol versus no intervention in metastatic HER2+ breast cancer patients receiving potentially cardiotoxic treatments.